Avalo Therapeutics reports FY24 EPS ($20.91) vs ($113.58) last year
Reports FY24 revenue $441k, consensus $224.5k. “2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has ...
Avalo Reports 2024 Financial Results and Recent Business Updates
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed ...
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b ...
The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...
Rolling Out15 小时
The hidden danger silently fueling disease in your body
Chronic inflammation fuels diseases like heart disease, diabetes, and cancer Learn how modern life triggers it and ways to ...
Medscape15 小时
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.
Avalo Therapeutics: Avalo Reports 2024 Financial Results and Recent Business Updates
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 ...
CBSE Class 12 Biotechnology Sample Paper 2025: Practise for Last Minute Revision, Download PDF
The Central Board of Secondary Education (CBSE) Senior Secondary Class 12 Biotechnology exam is on 21st March,2025. Therefore ...